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Abstract
METCAM/MUC18, a component of cellular membrane, is a cell adhesion mol-
ecule (CAM) in the Ig-like gene super-family. It is capable of carrying out general 
functions of CAMs, such as performing intercellular interactions and interaction of 
cell with extracellular matrix in tumor microenvironment, interacting with various 
signaling pathways, and regulating social behaviors of cells. METCAM/MUC18 
plays the tumor suppressor function in some cancers, such as colorectal cancer, 
nasopharyngeal carcinoma type I, one mouse melanoma subline K1735-9, ovarian 
cancer, pancreatic cancer, prostate cancer PC-3 cell line, and perhaps hemangioma. 
Possible mechanism in the METCAM/MUC18-mediated tumor suppression is pro-
posed. By taking advantage of the tumor suppressor function of METCAM/MUC18, 
recombinant METCAM/MUC18 proteins and other derived products may be used 
as therapeutic agents to treat these cancers.
Keywords: METCAM/MUC18, Ig-like CAM, in vivo tumor suppression,  
colorectal cancer, nasopharyngeal carcinoma, mouse melanoma, ovarian cancer, 
pancreatic cancer, prostate cancer, mouse models
1.  Introduction: tumor initiation and malignant progression is mainly 
controlled by two sets of genes as well as CAMs
Tumor/cancer is a genetic disease due to accumulated mutations or epigenetic 
alterations in our genetic material, DNA [1]. 80–90% of cancer risk comes from 
environmental factors and the remaining 10–20% risk from hereditary factors [2]. 
Environment in a broad sense includes both the physical containment and the social 
and cultural environment and its associated effects on our lifestyle choices. The 
environmental factors in the physical containment include chemicals (from polluted 
drinking water, air and soil, and diet), physical agents (UV and environmental 
radiation and medical radiation), biological agents (tumor viruses, bacteria, and 
parasites), and the lifestyle. These agents aim to attack our DNA in the somatic cells 
and resulting in accumulation of mutations and epigenetic alterations in our genes 
throughout our life time. Hereditary factors (lineage specific cues) include both the 
inherited genetic mutations and epigenetic imprinting in the germ cells that pass 
on from generation to generation. Tumor initiation and malignant progression are 
mainly caused by two sets of genes, such as the tumor-promoting genes (oncogenes) 
and the tumor suppressor genes, thus, mutations and epigenetic alterations in these 
two sets of genes are doom to be responsible for the tumorigenic process [2–4].
In addition to exogenous chemical agents, physical agents, and biological agents in 
the environment that cause mutations in the genes, endogenous metabolic processes 
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and chronic inflammation from our lifestyle choices produce free radicals that 
directly attack our DNA also resulting in mutations [5]. The major sources of free 
radicals are reactive oxygen species (ROS), which is a collective term for the unstable, 
reactive, partially reduced oxygen derivatives that are the normal by-products of our 
metabolic processes. They include hydrogen peroxide (H2O2), superoxide anion (O2
−), 
hypochlorous acid (HOCl), singlet oxygen (1O2), and hydroxyl radical (
•HO). ROS are 
also produced by the inflammatory macrophages and neutrophils and are spilled out 
to attack the DNA of bystander cells. ROS acts as the secondary messengers in cell sig-
naling and essential for various biological processes in both normal and cancer cells 
and as both tumor-promoting and tumor suppressing agents. To keep the system in 
check, ROS is balanced by intracellular anti-oxidant enzymes, that produce a number 
of anti-oxidants, such as glutathione (GSH) and thioredoxin (Txn), which are also 
present in our foodstuffs, to remove ROS. ROS production is a mechanism shared by 
most chemotherapeutics to trigger cell-death in cancer cells and unfortunately also to 
some extent in normal cells. Thus, ROS has conflicting roles as a secondary messenger 
in cancer cells as well as cancer-killers during cancer chemotherapy.
Most of the mutations in the oncogenes are dominant and thus manifest obvious 
phenotypes of increased proliferation and survival of tumor cells (gain-of-functions). In 
contrast, most of mutations in the tumor suppressor genes are recessive and thus do not 
manifest any phenotype until both copies of the gene are mutated or altered epigeneti-
cally (loss-of-functions). Some tumor suppressor genes are gate-keepers that directly 
affect proliferation and death, thus directly open to tumor formation. But some tumor 
suppressor genes are care-takers that affect DNA repair functions and genomic stability, 
thus increase mutation rate of all genes and indirectly affect proliferation [2, 6].
Epigenetic alterations may change the extent of methylation (either hypo- or 
hyper-methylation) in the regulatory regions of both oncogenes and tumor-sup-
pressor genes, thus affect the transcriptionally regulatory region of the genes and 
directly regulate transcriptional expression of the genes. Epigenetic alterations may 
also modify histones and non-histone proteins that affect chromosome remodeling, 
thus indirectly affect the transcription of the genes. Epigenetic alterations may also 
affect post-transcription processes (namely translational process or stability of 
mRNA) of the genes via microRNAs [7].
Besides the above traditional two sets of genes, other genes, such as CAMs, also 
contribute directly to the tumor initiation and progression or orchestrate the tumor 
microenvironment to affect the tumor progression [8]. CAMs are involved in several 
biological functions, such as tissue architecture, organ formation, blood vessel 
generation and angiogenesis, immune and inflammatory reactions, wound healing 
and social behaviors [8]. An altered expression of CAMs may have implications in 
tumorigenesis, since CAMs govern cellular social behaviors by directly contributing 
to cell adhesion and cross-talk with the intracellular signal transduction pathways [8]. 
As a consequence, an aberrant expression of CAMs is capable of changing mobility 
and invasiveness, influencing outlasting ability and proliferation of tumor cells, and 
altering new blood vessel formation [8]. It also affects distant organ-dissemination 
of carcinoma cells, because CAMs orchestrate complex interactions of tumor cells 
with various stromal cells in the tumor microenvironment, resulting in augmentation 
or reduction of the spreading potential of carcinoma cells [8]. Effects of the aber-
rant expression of the following CAMs on tumorigenesis and malignant progression 
are better studied, such as cadherin [9], integrins [10], CD44 [11], CEACAM [12], 
mucins [13], L1CAM [14], EpCAM [15], ALCAM [16] and METCAM/MUC18 [17]. 
Over the past several years, our team investigated the role of METCAM/MUC18 in 
several types of tumors, such as melanoma, breast, nasopharyngeal, ovarian and 
prostate cancers [18–36]. The resulting data showed a dual role of METCAM/MUC18 
as a tumor promotor or suppressor in these cancers [17, 37].
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2. METCAM/MUC18: an immunoglobulin-like (Ig-like) CAM
Originally, METCAM/MUC18 was first demonstrated to be abundantly expressed 
on the cellular membrane of most malignant human melanomas, hence named as 
MUC18. It has been implicated to play a pivotal role in the malignant progression 
of human melanoma, hence was named as MCAM and Mel-CAM) [38]. However, 
METCAM/MUC18 was found in subsequent studies not to be exclusively expressed 
in melanoma, and it did not initiate the transformation of normal cutaneous mela-
nocytes to melanoma either [39]. Instead, METCAM/MUC18 was also expressed 
in other epithelial tumors and it could initiate or promote the transformation of 
other epithelial cells into carcinomas [40]. Thus, METCAM/MUC18 also bears other 
names, such as S-endo1, CD146, A32, or METCAM [40, 41]. Later METCAM/MUC18 
was found to be able to suppress tumorigenesis in some cancer cell lines [17, 37, 40].
The human METCAM/MUC18 is a cell adhesion molecule (CAM) belonging to 
the Ig-like gene superfamily. The naked human METCAM/MUC18 is a single chain 
transmembrane protein of 65–72 kDa consisting in 646 amino acids with an extra-
cellular N-terminal domain of 558 amino acids, a 24 amino acids-transmembrane 
domain and a cytoplasmic domain of 64 residues (Figure 1) [38, 42].
Figure 1 shows that the N-terminal extra-cellular domain of the protein is com-
posed of a signal peptide sequence (SP) and five immunoglobulin-like domains and 
one X domain [37, 42]. The intracellular cytoplasmic domain has one, three, and one 
protein kinase consent sequences that are potentially to be phosphorylated by PKA, 
PKC, and CK2, respectively [37, 38, 42]. In addition, the METCAM/MUC18 usually 
has an apparent molecular weight of 110–150,000 because it is heavily glycosylated in 
all cell types. The amino acid sequence of huMETCAM/MUC18 reveals nine possible 
N-glycosylation sites, of which six are conserved between human and mouse proteins, 
in the extracellular domain. METCAM/MUC18 is conserved in mouse, in which the 
amino acid sequences of mouse METCAM/MUC18 (moMETCAM/MUC18) are 
72.6% identical to the huMETCAM/MUC18 [43]. Therefore, both human and mouse 
METCAM/MUC18’s are capable of performing similar general functions of CAMs, 
such as controlling cellular social behaviors by impacting the adhesion status of cells 
and modulating signaling. Furthermore, over-expression of both human and mouse 
METCAM/MUC18’s similarly affected tumor cells in in vitro motility and invasive-
ness, in vitro and in vivo tumorigenesis, and in vivo metastasis [42, 43].
Figure 1. 
The human METCAM/MUC18 (huMETCAM/MUC18). The figure represents the protein structure of 
huMETCAM/MUC18 with its 3 domains: (1) a large extracellular domain showing a signal peptide (SP), the 
five Ig-like variables (V1 and V2) and conserved (C1, C2, C2′ and C2″) domains, each of which held together 
by a disulfide bond, and one X domain; six conserved N-glycosylation sites indicated as wavy lines in V1, the 
interdomain C2′/C2″, C2″ and X domains; (2) a short transmembrane domain (TM); and (3) a cytoplasmic 
domain containing five potential phosphorylation sites (P).
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The huMETCAM/MUC18 is expressed in at least 10 normal tissues: hair follicular 
cells, smooth muscle cells, endothelial cells, cerebellum, basal cells of the lung, acti-
vated T cells, intermediate trophoblasts [44], breast epithelium [18, 19], nasopha-
ryngeal epithelium [23], and ovarian epithelium [27]. The protein is also expressed 
in several carcinomas, such as breast carcinoma, intermediate trophoblast tumors, 
melanoma, prostate adenocarcinoma, osteosarcoma, and others [17, 44]. Our studies 
also indicate that over-expression of METCAM/MUC18 augments tumorigenesis of 
breast carcinoma [18–20], nasopharyngeal carcinoma type III [24, 26], and prostate 
adenocarcinoma [34], but it does not have an obvious effect on tumorigenesis of 
most melanoma cell lines [21]. METCAM/MUC18 over-expression also initiates the 
distant organ-dissemination of prostate cancer [32, 33] and augments the distant 
organ-dissemination of melanoma [21] and breast carcinoma [45].
In contrast, over-expression of METCAM/MUC18 represses tumorigenesis of a 
mouse melanoma cell line, K1735-9 [22], nasopharyngeal carcinoma type I [24, 25] 
and perhaps hemangiomas [46]. METCAM/MUC18 over-expression also represses 
the distant organ-dissemination of the mouse melanoma cell line, K1735-9 [22].
3. METCAM/MUC18: a tumor suppressor in several types of cancer
3.1 Mouse melanoma
Over-expression of moMETCAM/MUC18 in one mouse melanoma cell line 
K1735 clone 10 (or K1735-10 subline) has no effect and that in another cell line 
K1735 clone 3 a slight suppression effect on subcutaneous tumorigenesis [21], but 
in K1735 clone 9 (or K1735-9 subline) it completely suppresses the subcutaneous 
tumorigenesis [22]. Thus, METCAM/MUC18 definitely acts as a tumor suppres-
sor for the K1735-9 subline, but may have a less obvious effect on two other K1735 
sublines, K1735-3 and K1735-10. In addition to its effect on tumorigenesis, over-
expression of moMETCAM/MUC18 in K1735-9 also completely suppressed lung 
nodule formation in immunocompetent syngeneic C3H brown mouse model. In 
contrast, over-expression of moMETCAM/MUC18 in K1735-3 and K1735-10 subline 
has an opposite effect (namely promotion) on lung nodule formation. In conclu-
sion, moMETCAM/MUC18 acts as a tumor suppressor with a different severity on 
different cell lines in a syngenetic mouse model [21, 22].
3.2 Nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) occurs in the non-lymphomatous, squamous 
epithelial lining of the posterior nasopharynx [24]. Histologically, three subtypes 
of NPC are defined according to World Health Organization (WHO) classification: 
WHO type I (keratinizing squamous cell carcinomas), WHO type II (non-keratin-
izing squamous cell carcinomas), and WHO type III (undifferentiated carcinomas) 
[24]. Three major risk factors suggested by epidemiological studies, such as genetic 
predisposition, dietary and environmental factors, and the Epstein Barr virus (EBV) 
infection, may cause the unusual occurrence of NPC in endemic areas [24–26]. 
However, the biological mechanisms of their involvement in cancer initiation, 
development or malignant progression are not well understood. Nevertheless, it 
could be hypothesized that altered cell adhesion molecules (CAMs) in NPC lead to 
tumorigenesis and malignant progression, since aberrant expression of CAMs, such 
as CD44, connexin 43, E-cadherin, and ICAM, has been associated with the progres-
sion of NPC [23]. In order to test this hypothesis, we previously studied the possible 
role of altered METCAM/MUC18 expression in nasopharyngeal carcinoma [23, 24].
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Therefore, we used immunohistochemistry method to determine gene expres-
sion at the protein level in seven tissue specimens of normal nasopharynx, 97 
specimens of three different types of NPC and also used immunoblot method to 
determine that in several cell lines established from type I and type III NPC [23]. 
The results showed a weak expression of the protein METCAM/MUC18 in 27% 
of the NPC tissues in contrast to all the normal nasopharynx tissues which exhib-
ited high expression of the protein. According to these results, we suggested that 
METCAM/MUC18 may play a tumor suppressor function in the development of 
NPC during the progression of the disease [23]. We then tested the hypothesis by 
transfecting the cDNA into two NPC cell lines which weakly expressed the protein 
and isolated the high-expressing clones for examining the effect of METCAM/
MUC18 over-expression on in vitro cellular behavior and in vivo tumorigenesis of 
the two NPC cell lines in athymic nude mice. Consistent with the hypothesis, we 
indeed observed that METCAM/MUC18 over-expression suppressed the tumor 
growth of NPC-TW01 cells, which were established from type I NPC [47], as 
previously shown [24, 25]. We thus conclude that METCAM/MUC18 plays a tumor 
suppressor role in the development of the type I NPC [24, 25].
Surprisingly, when a different cell line, NPC-TW04, was used for the similar set 
of the experiments we observed a completely opposite effect of METCAM/MUC18. 
We observed that over-expression of METCAM/MUC18 promoted in vitro and in 
vivo tumor growth of NPC-TW04 cells, which were established from type III NPC 
[47], as previously reported [24, 26]. We thus conclude that METCAM/MUC18 
plays a tumor promoter role in the development of the type III NPC [24, 26].
Taken together we hypothesized that METCAM/MC18 plays a dual suppressor 
and promotor role in the different types of NPC.
3.3 Ovarian carcinoma
Two independent groups showed that METCAM/MUC18 expression is cor-
related with the progression of ovarian cancer [27, 48], and it affects the in vitro 
behaviors of ovarian carcinoma cells [49]. However, the role of METCAM/
MUC18 in the progression of epithelial ovarian cancer has not been directly tested 
in animal models. To investigate this, we initiated the studies by testing the effect 
of over-expression of METCAM/MUC18 on the in vitro cellular behaviors and in 
vivo tumorigenesis and malignant progression of human ovarian cancer cell lines in 
nude mice. First, we used a human ovarian cell line, SK-OV-3, for testing the effects 
of METCAM/MUC18 expression on their in vitro motility and invasiveness, and in 
vivo tumor formation after subcutaneous (SC) injection and also in vivo progression 
after intraperitoneal (IP) injection in athymic nude mice. We observed that over-
expression of METCAM/MUC18 reduced in vitro motility and invasiveness [28] and 
suppressed in vivo tumorigenesis and malignant progression of the human ovarian 
cancer cell line SK-OV-3 [28]. Then, we used the other human ovarian cancer cell 
line, BG-1, for similar tests and also observed similar phenomenon [50].
In summary, we supplied in vitro and in vivo evidence to definitely support the 
conclusion that METCAM/MUC18 plays a suppressor role in the tumorigenesis and 
malignant progression of two human ovarian cancer cell lines [28, 50]. Our results 
suggest that METCAM/MUC18 is a strong candidate as a new tumor and metastasis 
suppressor in human ovarian cancer cells.
3.4 Prostate cancer
For the previous two decades, we have firmly established the notion that 
over-expression of METCAM/MUC18 promotes the tumorigenesis and metastasis 
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of human prostate cancer cell line LNCaP, which was established from lymphatic 
lesions [31–36]. To check if the conclusion is also extended to another human 
prostate cancer cell line DU145, we recently tested the effect of knocking down 
the endogenously expressed METCAM/MUC18 on tumorigenesis in a nude mouse 
system, since DU145 endogenously expressed a high level of METCAM/MUC18 
[51]. We found that knocking down of the endogenously expressed METCAM/
MUC18 with three shRNAs decreased the subcutaneous tumorigenesis in male 
nude mice in comparison to a control shRNA, as shown in Figure 2. We thus 
concluded that METCAM/MUC18 expression in DU145 cell line, which was 
established from brain lesions, plays a positive role in tumorigenesis (and perhaps 
metastasis) similar to in LNCaP cells.
In contrast, we recently used the similar knocking down strategy to test the 
effect of decreased the endogenous METCAM/MUC18 expression on in vivo 
tumorigenesis of another human prostate cancer cell line, PC-3, which was estab-
lished from bone lesions, surprisingly we found that knocking down the endog-
enously expressed METCAM/MUC18 increased the tumor proliferation of PC-3 
cells (which was opposite to that of DU145, as shown above in Figure 2), suggesting 
that expression of METCAM/MUC18 suppressed the tumorigenesis of the human 
prostate cancer cell line PC-3 [52], as shown in Figure 3.
Figure 3. 
Tumorigenicity of four shRNA-knockdown clones of PC-3. Effect of METCAM/MUC18 expression on in 
vivo tumorigenicity (Left) and final tumor weight (Right). (Left) Average tumor volumes from five mice 
S.C. injected with each of the 46 (control), 72, 24, and 27 clones/cells, which were transfected with the four 
corresponding shRNAs in pGIPZ vector, were plotted against time. (Right) Average final tumor weights from 
five mice S.C. injected with the same clones/cells and standard deviations were plotted at the end point of 
experiment. P values are shown in the figure by comparing the data to the control clone [52].
Figure 2. 
Tumorigenicity of four shRNA-knockdown clones of DU145. Effect of METCAM/MUC18 expression on in 
vivo tumorigenicity (Left) and final tumor weight (Right). (Left) Average tumor volumes from five mice 
S.C. injected with each of the 46 (control), 72, 24, and 27 clones/cells, which were transfected with four 
corresponding shRNAs in pGIPZ vector, were plotted against time. (Right) Average final tumor weights from 
five mice S.C. injected with the same clones/cells and standard deviations were plotted at the end point of 
experiment. P values are shown in the figure by comparing the data to the control clone [51].
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We thus conclude that METCAM/MUC18 serves as a tumor suppressor in the PC-3 
cell line, different from its role in two other prostate cancer cell lines (LNCaP and 
DU145), suggesting that prostate cancer cell lines established from different organs 
may have different intrinsic factors that modulate the function of METCAM/MUC18.
3.5 Colorectal cancer, hemangioma and pancreatic cancer
The protein METCAM/MUC18 is also expressed others cancers, such as angiosar-
coma, gestational trophoblastic tumors, Kaposi’s sarcoma, leiomyosarcoma, some lung 
squamous and small cell carcinomas, and some neuroblastoma [44]. However, its role 
in the development of most of these cancers is not well known. Recent meta-analysis 
suggests that high METCAM/MUC18 expression in many solid tumors appears to be 
associated with poor prognosis and patient survival [53]. However, in contrast to the 
conclusion, reduced expression of METCAM/MUC18 associates with the malignant 
progression of hemangioma [46]. Likewise, recent results of the effects of METCAM/
MUC18 expression on tumorigenesis of colorectal cancer and pancreatic cancer also 
appear to support the similar conclusion, as described next. Reduced expression of 
METCAM/MUC18 promotes tumorigenesis and stemness of colorectal cancer [54]. 
Targeting soluble METCAM/MUC18 with a neutralizing antibody inhibits vascular-
ization, growth and survival of METCAM/MUC18-positive pancreatic tumors [55]. 
Furthermore, attenuation of METCAM/MUC18 promotes pancreatic cancer progres-
sion [56]. Thus, the possible tumor and metastasis suppressor role of METCAM/
MUC18 in solid tumors appear to extend from mouse melanoma K1735–9 subline, 
ovarian cancer, and NPC type I, to colorectal cancer [54] and pancreatic cancer [55, 56], 
and perhaps hemangioma [46]. Table 1 summarizes the negative role of METCAM/
MUC18 in the tumor formation and/or cancer metastasis of seven tumors/cancers.
4. METCAM/MUC18: a tumor promoter in most solid tumors
In contrast to the above functions of METCAM/MUC18, recent work done on other 
solid tumors appears to be consistent with the meta-analysis results of solid tumors [53],  
Tumor/cancer cell lines Tumorigenesis Metastasis References
Colorectal cancer human cell lines HT-29, 
SW480, SW948, SW620, colo205, Lovo320, P6C
Suppression Not determined [54]
Hemangioma human cell lines HemEC, 
HDMEC
Possible 
suppression
Not determined [46]
Mouse melanoma cell line K1735-9 Suppression Suppression [22]
Mouse melanoma cell lines K1735-3, K1735-10 No effect or slight 
suppression
Increasing and 
affecting the late 
stage
[21]
Nasopharyngeal carcinoma type I cell line 
NPC-TW01
Suppression Not determined [24, 25]
Ovarian cancer cell lines SK-OV3, BG-1 Suppression Suppression [28, 50]
Pancreatic cancer human cell lines, 
UACC-1273, PANC1, C81-61, KP-2, SUIT-2, 
MIAPaca-2, HS766T and primary CAFs
Suppression Suppression [55, 56]
Prostate cancer human cell line PC-3 Suppression Not determined [52]
Table 1. 
The negative role of METCAM/MUC18 in tumor formation and/or cancer metastasis of seven tumor/cancer 
cell lines.
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as described next. For example, METCAM/MUC18 expression correlates with the epi-
thelial-mesenchymal transition (EMT) markers and a poor prognosis in gastric cancer 
[57]. Tumor up-take of glioma in an orthotopic xenograft mouse model correlates with 
the expression level of METCAM/MUC18 [58]. METCAM/MUC18 promotes metasta-
sis and predicts poor prognosis of hepatocellular carcinoma [59]. Increased expression 
of METCAM/MUC18 has been found in hepatocellular carcinoma (HCC) tumor 
tissues as compared with the matched adjacent normal liver tissues and the METCAM/
MUC18+ cells purified from HCC tumors and cells have significantly increased colony-
forming capacity consistent with the cancer stem cells or the tumor-initiating cells [60]. 
METCAM/MUC18 expression has been shown to express in 51% of non-small cell lung 
carcinoma (NSCLC) and positive expression of METCAM/MUC18 has been associated 
with a shorter survival of patients with adenocarcinomas and used to predict the poor 
overall survival in patients with lung adenocarcinomas [61–63]. METCAM/MUC18 
expression mediates acquisition of cancer stemness and enhances tumor invasion and 
metastasis in a mouse model [64]. High expression of METCAM/MUC18 correlates 
with intrapulmonary metastasis of NSCLC cells in a mouse model [65]. Consistent with 
the results, we showed in Figure 4 (Guang-Jer Wu, unpublished data) that METCAM/
MUC18 is expressed in a lung type II alveolar epithelial cell carcinoma cell, A549, 
and highly expressed in an adenocarcinoma cell line, H838, in comparison with its no 
expression in an immortalized normal embryonic WI38 cell line.
Furthermore, METCAM/MUC18 mediates chemoresistance of small cell lung 
carcinoma (SCLC) [66]. METCAM/MUC18 is expressed in osteosarcoma cell lines, 
but not in normal osteoblast cells [67]. Osteosarcoma is effectively treated with 
METCAM/MUC18 monoclonal antibodies [68, 69]. Transcription factor MEIS1 
activates METCAM/MUC18 expression to promote migration of mouse pancreatic 
tumor cell lines [70]. METCAM/MUC18 very likely promotes the formation of 
angiosarcoma, as supported by our preliminary results as described next. Mouse 
METCAM/MUC18 was expressed in one angiosarcoma clone, SVR, which was 
transfected with H-Ras, at a higher level than in the control cell line, an immortal-
ized normal endothelial cell line, MS-1 [71]. Furthermore, the tumorigenicity of 
the SVR cell line was higher than the control cell line, thus in direct association with 
the higher expression level of moMETCAM/MUC18 [40, 71]. This suggests that 
METCAM/MUC18 very likely promotes the formation of angiosarcoma [40, 71].  
Figure 4. 
Expression of METCAM/MUC18 in normal lung tissue (SV40-immortalized normal lung cells (WI38, lane 
2) and lung type II alveolar epithelial cell carcinoma cell (A549, lane 3) and lung primary adenocarcinoma 
(H838, lane 4) (from Guang-Jer Wu, unpublished data).
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Hence, the positive role played by the METCAM/MUC18 in the progression of solid 
tumors have been extended from breast cancer, human and mouse melanoma, 
prostate cancer to angiosarcoma [40, 71], gastric cancer [57], glioma [58], hepato-
cellular carcinoma [59, 60], non-small cell lung adenocarcinoma [61–65], small cell 
Tumor/cancer tissues or cell lines Tumorigenesis Metastasis References
Angiosarcoma human cell lines MS1, 
SVR
Increasing Not determined [40, 71]
Human breast cancer cell line MCF-7 Promotion Not determined [18]
Human breast cancer cell line SK-BR-3 Promotion Not determined [19, 20]
Human breast cancer cell lines 
MDA-MB-231 and MDA-MB-468
Promotion Promotion [19, 45]
Gastric cancer human tissues Promotion Not determined [57]
Glioma cell lines U87MG, U251 Promotion Not Determined [58]
Hepatocellular carcinoma human cell 
lines PLC/PRF/5, Huh7, MHCC97H& 
97 L HepG2, SMMC-7721, focus, 
YY-8103, LM3, HLF and primary HCC 
cell lines; normal liver cell line LO2
Promotion Not determined [59, 60]
Non-small cell lung cancer human cell 
lines A549, H23, H358, H460, H522, 
H838, HCC4006, H1650/ER, PC-9, 
PC9GR, and adenocarcinoma tissues
Promotion Promotion [61–65], our 
unpublished 
results
Small cell lung cancer human cell 
lines H69, H69AR, H82, H196, H209, 
DMS79
Promotion Not determined [66]
Clinical melanoma tissues and human 
melanoma cell lines SB-2, SK, XP-44
No effect Increasing and 
affecting the late 
stage
[38, 72, 73]
Mouse melanoma cell lines K1735-3, 
K1735-10
No effect 
or slight 
suppression
Increasing and 
affecting the late 
stage
[21]
Nasopharyngeal carcinoma type III 
human cell line NPC-TW04
Promotion Not determined [24, 26]
Osteosarcoma human cell lines CR9, 
MNNG-HOS, OHS, KPDX, KRIB, 
MG-63, shYY1, SaOS, SaOS-2, TE85, 
U20S
Promotion Augmentation [67–69]
Pancreatic cancer mouse cell lines 
ptf1a, LSL-Kras, LSL-Trp53, Pdx1,
Promotion Possible 
augmentation
[70]
Clinical prostate cancer human tissues Increasing Increasing and 
affecting initiation in 
the early stage (PIN)
[31]
Human prostate cancer cell line 
LNCaP
Increasing Increasing and 
affecting initiation in 
the early stage
[32, 34–36]
Human prostate cancer cell line DU145 Increasing Not determined [51]
Prostate adenocarcinoma in TRAMP 
mice
Increasing Increasing and 
affecting initiation in 
the early stage
[33]
Table 2. 
The positive role of METCAM/MUC18 in tumor formation and/or cancer metastasis of various tumors/cancers.
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lung cancer [66], osteosarcoma [67–69], and mouse pancreatic cancer [70]. Taken 
together, METCAM/MCU18 appears to be more prevalently in playing a positive 
role than a negative role in the tumorigenesis of solid tumors. Table 2 summarizes 
the positive role of METCAM/MUC18 in the tumor formation and/or cancer metas-
tasis of various tumors/cancers.
In conclusion, METCAM/MUC18 appears to play a dual role in the tumori-
genesis and perhaps also in metastasis of solid tumors. At this point, it is not 
clear why METCAM/MUC18 plays a dual role in this aspect. Since METCAM/
MUC18 only plays a dual role in different cell lines from the same type of cancer 
or in different type of cancers, but never in the same cancer cell line. It is logical 
to suggest a possible explanation that the intrinsic properties of each cancer cell 
line may provide specific co-factors or heterophilic ligands that may positively 
or negatively modulate the METCAM/MUC18-mediated tumorigenesis and 
metastasis. This can be readily scrutinized by identifying these specific intrinsic 
co-factors or heterophilic ligands by using immunological co-precipitation 
method in the future studies. This approach is feasible as described in one of the 
following sections, Section 5.1.
5. Putative mechanisms
Since the huMETCAM/MUC18 was first discovered in the 1980s, three groups 
have worked on the role of huMETCAM/MUC18 in melanoma metastasis [38, 
39, 72, 73], another group on the role of huMETCAM/MUC18 in the biology of 
endothelial cells [41], and our group joined in the effort to study the role of huMET-
CAM/MUC18 in the progression of mouse melanoma [43] and prostate cancer 
[31–36, 51, 52], and later breast cancer [18–20], ovarian cancer [27–30], and NPC 
[23–26], as described above. Recently, more groups have participated in further 
exploring the possible role of METCAM/MUC18 in other solid tumors in different 
organs, such as colorectum [54], gastro-organ [57], glioma [58], liver [59, 60], lung 
[61–66], pancreas [55, 56, 70], and bone [67–69]. Preliminary work in leiomyosar-
coma, esophagus squamous cell carcinoma, clear cell renal sarcoma, and gallblad-
der adenocarcinoma are also beginning to emerge [53].
After many decades of group effort, we are beginning to understand the biol-
ogy of METCAM/MUC18-mediated tumor progression. However, the biological 
mechanisms describing the role of METCAM/MUC18 in tumorigenesis and malig-
nant progression are still not well clarified such as: the protein’s domain involved 
in cell adhesion, the domain which mediates the interactions of tumor cells with 
the tumor microenvironment leading to tumor progression and in the METCAM/
MUC18-mediated tumorigenesis and malignant progression, and the effects of 
N-glycosylation on the functions of METCAM/MUC18 in tumorigenesis. Though 
the huMETCAM/MUC18-mediated outside-in and inside-out signaling in endo-
thelial cells are understood to some extent, and the METCAM/MUC18-mediated 
signaling, which is leading to the progression of various cancer cells, are not much 
known. How METCAM/MUC18 is positively or negatively regulated at the level of 
transcription in different cancer cells remains minimally known. As such, the fol-
lowing five important aspects are much needed for immediate future studies, such 
as different kinds or quantities of co-factors or heterophilic ligand(s) in different 
cancer cell lines, contributions of different domains of the protein, different signal-
ing pathways involved, differential regulation at the transcription level in tumors of 
different organs, and possible different extent of N-glycosylation in different cancer 
cell lines, which may critically modulate the function of METCAM/MUC18 in 
tumor progression.
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5.1 The heterophilic ligands of METCAM/MUC18
The heterophilic ligands of METCAM/MUC18 may play an important role in the 
cell-cell and cell-extra-cellular matrix interactions and cancer metastasis. Our pre-
liminary results suggest that the 72 kDa protein identified by immunoprecipitation 
method may be one of the heterophilic ligands for METCAM/MUC18, as shown in 
Figure 5 [40].
As shown in Figure 5, the putative heterophilic ligand 72 kDa is highly expressed 
in the PC-3 cell line, but much less in the DU145 cell line. This may reveal a possible 
explanation for the different role of huMETCAM/MUC18 in the tumorigenicity of 
the two prostate cancer cell lines [40].
5.2  The domains of huMETCAM/MUC18 required for tumorigenesis and 
metastasis
The relation of the protein structure of huMETCAM/MUC18 to its functions 
in tumorigenesis and metastasis have not been systematically defined. To begin 
addressing this question, we have generated mutants deleted different domains of 
huMETCAM/MUC18 by using a special PCR method [74] and used them to deter-
mine their contribution to tumorigenesis. Surprisingly, our results showed that the 
ecto-domain of huMETCAM/MUC18 induced tumorigenesis in LNCaP cells in nude 
mice, as well as the whole wild type of cDNA. These preliminary results suggested 
Figure 5. 
Putative heterophilic ligand of METCAM/MUC18 in PC-3 and DU145 cell lines.
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the key role of the ecto-domain in tumorigenesis induction in prostate cancer cells 
in vivo. This may implicate a puzzling notion that the cytoplasmic domain was not 
essential for this process (Guang-Jer Wu, data not shown). However, the critical 
direct test of using only the cytoplasmic domain for inducing tumor has not been 
performed for LNCaP cells. From the above puzzling observation, it is very clear 
that a systematic study has also to be performed in other cancer cell lines before a 
definitive conclusion can be drawn.
5.3  Signaling pathways in the METCAM/MUC18-mediated tumorigenesis and 
cancer metastasis
The huMETCAM/MUC18 contains three sites which are potentially phosphory-
lated by PKC, PKA and CK2 in the cytoplasmic tail [38, 42]. However, these putative 
phosphorylation sites have not been biochemically proven. Thus, the immediate 
question to be answered is that how many sites in the cytoplasmic tail of the native 
METCAM/MUC18 protein, which are to be isolated from different cancer cell lines, are 
actually phosphorylated? Which protein kinase is responsible for the phosphorylation? 
After this is answered, then we can further study how METCAM/MUC18 mediates 
crosstalk and networking with different signal pathways and to see if it is similar to or 
different from the cytoplasmic tails of other CAMs [41, 75–77]. Knowledge learned 
from other CAMs seem point to one aspect that METCAM/MUC18, as an integral 
membrane protein and a cell adhesion molecule, should mediate inside-in, inside-out, 
and outside-in signals to participate in intercellular communication and interaction of 
cell with extra-cellular matrix, which results in impacting cell motility and invasive-
ness [78, 79]. Furthermore, its interaction with co-factors or cognate heterophilic 
ligand(s) may alter these signals, which in turn should affect intrinsic tumor prolifera-
tion or impact tumor angiogenesis and/or mediate targeting to specific organs and pro-
moting metastasis. Moreover, METCAM/MUC18 may interact with various hormonal 
receptors, growth or anti-growth factors/receptors, various chemokines/receptors, 
and the Ca2+-mediated signaling members, which in turn affect the process of tumor 
progression. Figure 6 summarizes the possible preliminary crosstalk of huMETCAM/
MUC18 with many members of signal transduction pathways that may affect its func-
tion during tumor initiation and development and malignant progression.
5.4 Regulation of the huMETCAM/MUC18 gene transcription
The mechanism of transcriptional control of METCAM/MUC18 gene is mini-
mally studied [17]. Up to now, only the 900 bp sequences in the core promoter 
region of the huMETCAM/MUC18 gene are well-characterized [80]. This core 
promoter is rich in GC sequences but does not contain a TATA box. It includes many 
consensus sequences presumably as putative binding sites for various transcription 
regulatory factors, such as SP-1, CREB [81], AP-2 [82, 83], c-Myb [84], N-Oct2 
(Brn2) [85], Ets [86], CArG [87], and Egr-1 [88]. In addition, it also contains three 
insulin responsive elements (one Ets and two E-box motifs) [89], suggesting that 
huMETCAM/MUC18 gene expression may respond to the cue of various growth 
signals [37, 40], as shown in Figure 7.
In addition, some sequences upstream of the minimal core promoter sequences 
should also be expected for conferring the tissue-specific expression of the huMET-
CAM/MUC18 gene [90]. Recently this notion has been definitely supported by a 
finding that Ets sequence in the 10 kilo-bp up-stream region is involved in the regu-
lation of the expression of huMETCAM/MUC18 gene [91]. We have also engaged 
in this task by searching the sequence of the up-stream region of the huMETCAM/
MUC18 promoter in the Celera or other web sites. By taking advantage of the 
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known sequence searched, we designed many pairs of primers to screening a 
genomic library and obtained several phage clones which contain at least 4 kilo-bp 
of the gene for future studies (Guang-Jer Wu, unpublished data).
The epigenetic control of the expression of huMETCAM/MUC18 gene has not 
been extensively studied in NPC, though it has been implicated [92]. This is because 
huMETCAM/MUC18 gene is located at the locus of human chromosome 11q23.3 
that has been shown to be hypermethylated in NPC, suggesting that the expression 
of this gene may be regulated by epigenetic controls [93]. To support this notion, 
our preliminary results of treating NPC cell lines with 5-Aza-2′-deoxycytidine 
(Aza-C) showed that after the treatment with Aza-C, METCAM/MUC18 expres-
sion was somewhat elevated in the NPC-TW01 cell line, but not in the NPC-TW04 
cell line (Guang-Jer Wu, unpublished data). METCAM/MUC18 has also been shown 
to be methylated in most of the early stage of prostate cancer [94]. Further system-
atic studies in this aspect should be very interesting and rewarding in the future.
Figure 6. 
METCAM/MUC18-mediated signal transduction in tumorigenesis and malignant progression.
Figure 7. 
Putative transcription factor-recognized motifs in the 900 bp core promoter and 5–10 kilo bp up-stream region 
of the huMETCAM/MUC18 gene.
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5.5  The possible roles of glycosylation on the protein of METCAM/MUC18 in 
tumorigenesis and tumor progression
Glycosylation of a protein may affect the proper folding, stability, and/or 
activity of a protein [95], however, the possible roles of glycosylation in the func-
tion of MCETCAM/MUC18 protein have not been explored. The glycosylation 
of METCAM/MUC18 may also affect its ability in inducing/promoting or sup-
pressing the metastasis of cancer cells [95–99]. Both huMETCAM/MUC18 and 
moMETCAM/MUC18 may very likely to be heavily glycosylated, sialylated, and 
post-translationally modified, because both have an apparent molecular weight of 
about 110–150 kDa, which is much more than the naked protein with a molecular 
weight of about 65–70 kDa [100]. To initiate the study, we subjected the huMET-
CAM/MUC18, which was expressed in a human cancer cell line, to the digestion 
with N-glycosidase F, neuraminidase (sialidase), O-glycosidase, or endoglycosi-
dase H, and we observed that the apparent molecular weight of the protein was 
decreased after digestion with N-glycosidase F and neuraminidase (sialidase), but 
not with O-glycosidase or endoglycosidase H [37, 40]. From this, we suggested 
that both sialic acid and N-glycans are probably the major carbohydrate side chains 
of huMETCAM/MUC18. It is also possible that glycosylation may differ depend-
ing on the type of cancers. Thus, we suggested that different N-glycans at the 
N-glycosylation sites of huMETCAM/MUC18 may differ in different cancer cell 
lines, which may have significant positive or negative impacts on their EMT abili-
ties as well as tumorigenesis and metastasis. According to our hypothesis, a recent 
study described GCNT3 as an up-stream regulator of METCAM/MUC18. Moreover, 
GCNT3 glycosylates METCAM/MUC18 and extends its half-life which results in 
further elevation of S100A8/A9-mediated cellular motility in melanoma cells [101].
By searching in the primary sequence of the human huMETCAM/MUC18 
protein, nine potential N-glycosylation sites (Asn-X-Ser/Thr or N-X-S/T sites) 
have been revealed [37, 38, 40, 42], whereas only seven sites found in the mouse 
METCAM/MUC18 [43]. Six N-glycosylation sites are conserved between the 
two proteins: 56/58 NL/FS, 418/420NRT, 449/451NLS, 467NGT/469NGS, 
507NTS/509NTT, and 544/546NST [37, 38, 40, 42]. We suggest that only these six 
conserved N-glycosylation sites are actually glycosylated, because the apparent 
molecular weights of human METCAM/MUC18 and mouse METCAM/MUC18 
are similar in the SDS gel. All the N-glycosylation sites are located in the external 
region of the protein, such as the domains of V1, C′, C″ and X. First, all these six 
sites should be biochemically identified before further molecular genetic task. 
Then, we will use genetic tools to alter the N-glycosylation sites. The mutants will 
be transfected back into cancer cell lines without the endogenous expression of the 
protein. The clones, which only express these mutated METCAM/MUC18, will be 
used for various in vitro and in vivo experiments to test the effect of N-glycosylation 
on the function huMETCAM/MUC18. They also will be used for testing effects on 
in vitro cell–cell aggregation and cell-extracellular matrix adhesion and on in vivo 
tumorigenesis and metastasis of human cancer cells. We anticipate that systematic 
studies on this aspect should be very informative to reveal the essential role of 
N-glycosylation played in the METCAM/MUC18-mediated tumor progression.
6. Conclusions
METCAM/MUC18 plays a key role in suppressing the progression of colorectal 
cancer, one mouse melanoma cell line, NPC type I, ovarian cancer, pancreatic cancer, 
prostate cancer PC-3 cell line, and perhaps hemangioma and possibly in other cancers. 
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On the other hand, METCAM/MUC18 also play a key positive function in the progres-
sion of breast cancer, gastric cancer, hepatocellular carcinoma, lung cancer, melanoma, 
NPC type III, pancreatic cancer, and prostate cancer. To further understand its role in 
these processes, it is essential to further identify its co-factor regulators and cognate 
heterophilic ligands, define its functional domains, and study its crosstalk with mem-
bers of various signal transduction pathways, the regulation of its expression at the 
level of transcription, and effects of N-glycosylation on the functions of the protein.
7. Research perspectives and clinical applications
7.1 Research perspectives
The current studies have laid an important biological basis for inspiring future 
intense investigation to further understand the detailed knowledge of METCAM/
MUC18-mediated suppression of tumorigenesis and metastasis of various cancer cell 
lines. For this purpose besides those have been described above, other future endeav-
ors may include: (a) understanding three major mechanisms involved in METCAM/
MUC18-induced tumor and metastasis dormancy, such as key players participated in 
inhibition of intrinsic growth capability, key chemokines and cytokines participated 
in suppression of immunological responses, and key pro-angiogenic and anti-
angiogenic factors participated in the reduction of angiogenesis [102], (b) identifica-
tion of possible miRNAs and non-coding RNAs participated in the process upstream 
and downstream of METCAM/MUC18 [103], and (c) possible clinical applications 
should be explored. Precaution should be taken that a complete picture may only be 
possibly constructed after all the above studies are successfully executed.
7.2 Clinical applications
The majority of the cancer-associated mortality is due to dissemination of 
primary tumor to distant organs (metastasis). If we are able to decrease or stop 
the metastatic propensity of cancer cells and keep them stayed only at the primary 
site, it should be a major success in cancer therapy. Alternatively, it is also a major 
success if we are able to control cancer cells at the state of dormancy or remaining 
them at the stage of micro-metastatic lesions [104]. Thus, similar to other tumor 
and metastasis suppressors, such as KISS1, KAI1, nm23, MAP2K4, and some 
micro-RNAs, METCAM/MUC18 may be used as a new therapeutic target for some 
clinical cancer treatments [105]. Strategically four major approaches may be taken 
for this purpose: (a) use gene therapeutic method to restore the functional copy of 
the suppressor genes or use epigenetic method to re-activate the genes. For gene 
therapy, the METCAM/MUC18 cDNA gene may be transported by an adenovirus-
associated virus vector or a replication-defective adenovirus [106]. The human 
METCAM/MUC18 gene, located on 11q23-3 chromosome may be targeted with 
clinical reagents to reverse epigenetic repression, like Aza-C [107], or to change 
histone modifications to induce remodeling of the chromosome [108], (b) dispense 
recombinant proteins directly to the patients. For this approach, a complete copy 
or a partial portion of the METCAM/MUC18 recombinant protein, oligopeptides, 
or small molecule mimetics of METCAM/MUC18 may be directly dispensed to 
cancer patients, (c) target at downstream key members in the signaling pathways 
which are activated by the loss of the suppressor function, and (d) the co-factors 
or the cognate heterophilic ligand(s) of METCAM/MUC18 may be targeted. The 
above strategies may be used in single, or better in combination for treating the 
patients for the purpose of holding tumor cells at the primary sites, stopping them 
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of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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in a dormant state, or keeping the disseminating cancer cells at the state of micro-
metastases. However, the dual role of METCAM/MUC18 in cancer progression 
may limit the above clinical applications to only cancers exhibiting an anti-tumor 
activity mediated by METCAM/MUC18.
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